Impact of cyclic hypoxia on HIF-1α regulation in endothelial cells - New insights for anti-tumor treatments

FEBS Journal

Volumn 276, Issue 2, 2009, Pages 509-518

  Martinive, Philippe ^a,b   Defresne, Florence ^a   Quaghebeur, Elise ^a   Daneau, Géraldine ^a   Crokart, Nathalie ^a   Grégoire, Vincent ^a   Gallez, Bernard ^a   Dessy, Chantal ^a   Feron, Olivier ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Akt; Endothelial cells; HIF; Hypoxia; Nitric oxide

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ARTICLE; CELL HYPOXIA; CELL SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; HUMAN CELL; OXYGEN CONSUMPTION; PRIORITY JOURNAL; REOXYGENATION; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL SURVIVAL; CELLS, CULTURED; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NITRIC OXIDE SYNTHASE TYPE III; OXYGEN; PHOSPHORYLATION; PROTEASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 58149165153     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2008.06798.x     Document Type: Article

References (38)

1. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3, 721 732.
2. Michiels C (2004) Physiological and pathological responses to hypoxia. Am J Pathol 164, 1875 1882.
3. Pouyssegur J, Dayan F Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437 443.
4. Vincent KA, Feron O Kelly RA (2002) Harnessing the response to tissue hypoxia: HIF-1 α and therapeutic angiogenesis. Trends Cardiovasc Med 12, 362 367.
5. Schofield CJ Ratcliffe PJ (2004) Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5, 343 354.
6. Zhou J Brune B (2006) Cytokines and hormones in the regulation of hypoxia inducible factor-1α (HIF-1α). Cardiovasc Hematol Agents Med Chem 4, 189 197.
7. Hagen T, Taylor CT, Lam F Moncada S (2003) Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1α. Science 302, 1975 1978.
8. Metzen E, Zhou J, Jelkmann W, Fandrey J Brune B (2003) Nitric oxide impairs normoxic degradation of HIF-1α by inhibition of prolyl hydroxylases. Mol Biol Cell 14, 3470 3481.
9. Li F, Sonveaux P, Rabbani ZN, Liu S, Yan B, Huang Q, Vujaskovic Z, Dewhirst MW Li CY (2007) Regulation of HIF-1α stability through S-nitrosylation. Mol Cell 26, 63 74.
10. Quintero M, Brennan PA, Thomas GJ Moncada S (2006) Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1α in cancer: role of free radical formation. Cancer Res 66, 770 774.
11. Quintero M, Colombo SL, Godfrey A Moncada S (2006) Mitochondria as signaling organelles in the vascular endothelium. Proc Natl Acad Sci USA 103, 5379 5384.
12. Chaplin DJ, Olive PL Durand RE (1987) Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res 47, 597 601.
13. Coleman CN (1988) Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity. J Natl Cancer Inst 80, 310 317.
14. Chaplin DJ Hill SA (1995) Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours. Br J Cancer 71, 1210 1213.
15. Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, Papahadjopoulos D, Hong K Dewhirst MW (1996) Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 56, 5522 5528.
16. Dewhirst MW (1998) Concepts of oxygen transport at the microcirculatory level. Semin Radiat Oncol 8, 143 150.
17. Brurberg KG, Graff BA Rofstad EK (2003) Temporal heterogeneity in oxygen tension in human melanoma xenografts. Br J Cancer 89, 350 356.
18. 2 in poorly and well-oxygenated spontaneous canine tumors before and during fractionated radiation therapy. Radiother Oncol 77, 220 226.
19. Baudelet C, Ansiaux R, Jordan BF, Havaux X, Macq B Gallez B (2004) Physiological noise in murine solid tumours using T2*-weighted gradient-echo imaging: a marker of tumour acute hypoxia? Phys Med Biol 49, 3389 3411.
20. Lanzen J, Braun RD, Klitzman B, Brizel D, Secomb TW Dewhirst MW (2006) Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Res 66, 2219 2223.
21. Martinive P, De Wever J, Bouzin C, Baudelet C, Sonveaux P, Gregoire V, Gallez B Feron O (2006) Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery. Mol Cancer Ther 5, 1620 1627.
22. Gatenby RA Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4, 891 899.
23. Dewhirst MW, Cao Y Moeller B (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8, 425 437.
24. Martinive P, Defresne F, Bouzin C, Saliez J, Lair F, Gregoire V, Michiels C, Dessy C Feron O (2006) Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res 66, 11736 11744.
25. 2) inside tumors? Magn Reson Med 48, 980 986.
26. Baudelet C, Cron GO, Ansiaux R, Crokart N, Dewever J, Feron O Gallez B (2006) The role of vessel maturation and vessel functionality in spontaneous fluctuations of T2*-weighted GRE signal within tumors. NMR Biomed 19, 69 76.
27. Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A, Fisher RJ, Shoemaker RH Melillo G (2005) Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 65, 9047 9055.
28. Brahimi-Horn C, Mazure N Pouyssegur J (2005) Signalling via the hypoxia-inducible factor-1α requires multiple posttranslational modifications. Cell Signal 17, 1 9.
29. Minet E, Michel G, Mottet D, Raes M Michiels C (2001) Transduction pathways involved in hypoxia-inducible factor-1 phosphorylation and activation. Free Radic Biol Med 31, 847 855.
30. Zhou J, Schmid T, Frank R Brune B (2004) PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1α from pVHL-independent degradation. J Biol Chem 279, 13506 13513.
31. Cardenas-Navia LI, Mace D, Richardson RA, Wilson DF, Shan S Dewhirst MW (2008) The pervasive presence of fluctuating oxygenation in tumors. Cancer Res 68, 5812 5819.
32. 2 +-dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor-exposed endothelial cells. J Biol Chem 276, 32663 32669.
33. Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL Feron O (2001) Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 89, 866 873.
34. Powis G, Ihle N Kirkpatrick DL (2006) Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway. Clin Cancer Res, 12, 2964 2966.
35. Sonveaux P, Martinive P, Dewever J, Batova Z, Daneau G, Pelat M, Ghisdal P, Gregoire V, Dessy C, Balligand JL et al. (2004) Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ Res 95, 154 161.
36. James PE, Jackson SK, Grinberg OY Swartz HM (1995) The effects of endotoxin on oxygen consumption of various cell types in vitro: an EPR oximetry study. Free Radic Biol Med 18, 641 647.
37. Gallez B, Baudelet C Jordan BF (2004) Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications. NMR Biomed 17, 240 262.
38. Jordan BF, Gregoire V, Demeure RJ, Sonveaux P, Feron O, O'Hara J, Vanhulle VP, Delzenne N Gallez B (2002) Insulin increases the sensitivity of tumors to irradiation: involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption. Cancer Res 62, 3555 3561.